*´ºÉ«Ö±²¥

Many African leaders and advocacy groups say of access to COVID-19 treatment tools, vaccines and testing equipment — that many richer countries bought up in huge quantities — after the pandemic was declared in 2020.

WHO, advocacy groups, the European Union and others want to help Africa get better prepared for the next pandemic, which many health experts say is inevitable. When the coronavirus pandemic began, South Africa was the only country in Africa with any ability to produce vaccines, officials say, and the continent produced a tiny fraction of all vaccines worldwide.

“Africa produces only 2% of the vaccines it uses, and the goal that we have set is that by 2040 the production is increased to reach 60%," Macron said at the launch event. "France and Europe have supported this ambition since 2021 with 1.3 billion euros (allocated), and we need to accelerate it.�

WHO failed in its efforts to help countries agree to a “pandemic treaty� — to improve preparedness and response to pandemics — before its annual meeting last month. The project was shelved largely over disagreements about sharing of information about pathogens that cause epidemics and the high-tech tools used to fight them.

Negotiators will resume work on the treaty in hopes of clinching a deal by the next WHO annual meeting in 2025.

Thursday’s event in Paris also aims to give a funding boost to Gavi, the Vaccine Alliance, a public-private partnership that helps get needed vaccines to developing countries around the world.

Gavi says the project aims to make up to $1 billion available over the next decade to help increase Africa’s manufacturing base, to improve global vaccines markets and improve preparedness and response to pandemics and outbreaks like HIV, malaria, tuberculosis and COVID-19.

The Geneva-based alliance says the accelerator will inject funds into manufacturers in Africa once they hit supply and regulatory milestones, with an aim to use market forces to drive down prices and encourage investment upstream.

Officials say the project will explore issues like technology transfer — which has been resisted by some Western countries with powerful pharmaceutical companies — as well as the possible creation of a African medicines agency and tackling regulatory hurdles faced in Africa’s patchwork of legal systems.

___

Jamey Keaten reported from Geneva.